JP6802150B2 - がん治療のための免疫療法 - Google Patents

がん治療のための免疫療法 Download PDF

Info

Publication number
JP6802150B2
JP6802150B2 JP2017508517A JP2017508517A JP6802150B2 JP 6802150 B2 JP6802150 B2 JP 6802150B2 JP 2017508517 A JP2017508517 A JP 2017508517A JP 2017508517 A JP2017508517 A JP 2017508517A JP 6802150 B2 JP6802150 B2 JP 6802150B2
Authority
JP
Japan
Prior art keywords
dnt
cells
aml
cell
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527551A (ja
JP2017527551A5 (enExample
Inventor
リ チャン，
リ チャン，
ジョン ボク リー，
ジョン ボク リー，
ブランソン チェン，
ブランソン チェン，
Original Assignee
ユニバーシティー ヘルス ネットワーク
ユニバーシティー ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー ヘルス ネットワーク, ユニバーシティー ヘルス ネットワーク filed Critical ユニバーシティー ヘルス ネットワーク
Publication of JP2017527551A publication Critical patent/JP2017527551A/ja
Publication of JP2017527551A5 publication Critical patent/JP2017527551A5/ja
Application granted granted Critical
Publication of JP6802150B2 publication Critical patent/JP6802150B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
JP2017508517A 2014-08-15 2015-08-17 がん治療のための免疫療法 Active JP6802150B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037889P 2014-08-15 2014-08-15
US62/037,889 2014-08-15
PCT/CA2015/050780 WO2016023134A1 (en) 2014-08-15 2015-08-17 Immunotherapy for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2017527551A JP2017527551A (ja) 2017-09-21
JP2017527551A5 JP2017527551A5 (enExample) 2018-09-27
JP6802150B2 true JP6802150B2 (ja) 2020-12-16

Family

ID=55303743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508517A Active JP6802150B2 (ja) 2014-08-15 2015-08-17 がん治療のための免疫療法

Country Status (7)

Country Link
US (1) US10517937B2 (enExample)
EP (1) EP3180011B1 (enExample)
JP (1) JP6802150B2 (enExample)
CN (1) CN107073039B (enExample)
CA (1) CA2994462C (enExample)
ES (1) ES2869624T3 (enExample)
WO (1) WO2016023134A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046768A1 (en) * 2018-08-09 2020-02-13 University Health Network Double negative t cells and pd-1 blockade for the treatment of cancer
CA3123467A1 (en) * 2018-12-19 2020-06-25 University Health Network Production and therapeutic use of off-the-shelf double negative t cells
CN115362253B (zh) * 2020-02-07 2025-11-11 大学健康网络 利用维奈托克增强t细胞的方法
CN113528434A (zh) * 2020-04-20 2021-10-22 瑞创生物技术有限公司 一种通用型供临床多次回输异体dnt细胞的高效体外扩增方法
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR273760A (enExample)
US6953576B2 (en) 2000-08-21 2005-10-11 University Health Network Method of modulating tumor immunity
CN101313061B (zh) * 2005-11-18 2013-05-15 大学健康网络 扩增双阴性t细胞的方法
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
CA3021226A1 (en) 2015-05-11 2016-11-17 University Health Network Method for expansion of double negative regulatory t cells
US10201572B2 (en) * 2015-09-15 2019-02-12 University Health Network Combination therapy with double negative T-cells

Also Published As

Publication number Publication date
CA2994462A1 (en) 2016-02-18
JP2017527551A (ja) 2017-09-21
US10517937B2 (en) 2019-12-31
ES2869624T3 (es) 2021-10-25
EP3180011B1 (en) 2021-03-17
CN107073039A (zh) 2017-08-18
EP3180011A1 (en) 2017-06-21
CA2994462C (en) 2023-12-19
WO2016023134A1 (en) 2016-02-18
CN107073039B (zh) 2021-07-20
US20170274060A1 (en) 2017-09-28
EP3180011A4 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
Lamb et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Yu et al. Research progress on dendritic cell vaccines in cancer immunotherapy
Hadiloo et al. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Rossi et al. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
Taniguchi et al. Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
GB2605540A (en) Tumor infiltrating lymphocytes and methods of therapy
KR20180134419A (ko) 세포성 면역요법을 위한 조성물 및 방법
JP7105188B2 (ja) 幹細胞移植方法
JP6802150B2 (ja) がん治療のための免疫療法
Riether et al. From “magic bullets” to specific cancer immunotherapy
Kiaei et al. Advances in natural killer cell therapies for breast cancer
JP2021519087A (ja) エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用
US20210008110A1 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
CA2942214C (en) Combination therapy with double negative t-cells
Dellabona et al. On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies
US20220152169A1 (en) Colorectal cancer tumor cell vaccines
CN114729314A (zh) 用于癌症治疗的组合癌症疗法和细胞因子控制疗法
US20240122986A1 (en) Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
WO2019028337A1 (en) TREATMENT AND INHIBITION OF LEUKEMIA USING NK-92 CELLS
Hasan et al. Non-engineered adoptive T cell therapy
Low et al. Immune cell selection and isolation
MAMACHE Cell and gene therapy Master 2 option immunology
Diamantoudis et al. Assessing the Hematological Cancer Stem Cell Landscape to Improve Immunotherapy Clinical Decisions
Ali Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine against Pancreatic Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200625

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200820

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201126

R150 Certificate of patent or registration of utility model

Ref document number: 6802150

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250